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Reactive oxygen species and tumor biology are intertwined in a complex web, making it difficult to understand which came 
first, whether oxidants are required for tumor cell growth, and whether oxidant stress can be exploited therapeutically. Evidence 
suggests that transformed cells use ROS signals to drive proliferation and other events required for tumor progression. This 
confers a state of increased basal oxidative stress, making them vulnerable to chemotherapeutic agents that further augment 
ROS generation or that weaken antioxidant defenses of the cell. In this respect, it appears that tumor cells may die by the same 
systems they require.Reactive oxygen species (ROS) and 
cellular oxidant stress have long been 
associated with cancer. However, the 
nature of this association is both com-
plex and at times paradoxical, as it 
appears that (1) ROS and oxidant stress 
may induce cancer; (2) transformed cells 
appear to generate more ROS than do 
normal cells; (3) the thioredoxin antioxi-
dant system is paradoxically amplified 
in malignant cells; (4) stimulation of cell 
cycle progression by growth factors, or 
by mutations that activate the recep-
tor tyrosine kinase signaling pathway, 
involves an increase in ROS signaling; 
and (5) diverse cancer chemothera-
peutic agents may be selectively toxic 
to tumor cells because they augment 
oxidant stress and push these already 
stressed cells beyond their limit. These 
connections are still not fully understood 
but are worth examining individually.
Induction of cancer by ROS
According to the mitochondrial para-
digm of cancer (Wallace, 2005), muta-
tions in nuclear or mitochondrial genes 
encoding components of the mitochon-
drial electron transport chain (ETC) can 
lead to an increase in ROS generation. 
This occurs when electron transfer is 
partially inhibited, leading to accumula-
tion of electrons at sites along the ETC 
where they can be captured by O2, lead-
ing to the formation of superoxide. This 
radical is rapidly dismuted by superoxide 
dismutase yielding hydrogen peroxide 
(H2O2), which can diffuse to the nucleus 
and attack DNA, thereby contributing to 
genetic instability. An example of this 
process has been described in prostate 
cancer, where mutations in mitochondrial 
DNA (which encodes specific subunits of 
the ETC) have been linked to increases 
in ROS production and tumor progres-
sion in prostate cancer models (Petros 
et al., 2005). Although the field is still 
emerging, mounting evidence supports 
the idea that chronic increases in ROS 
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ute to cancer progression by amplifying 
genomic instability.
Enhanced ROS generation by  
cancer cells
Previous studies suggest that can-
cer cells normally produce more ROS 
than do normal cells (Szatrowski and 
Nathan, 1991). One of the difficulties in 
testing this hypothesis arises from a lack 
of a comparable “normal cell” to use as 
a control. Some cell types have higher 
metabolic activities than do others, and 
these differences could easily trans-
late into higher rates of mitochondrial 
ROS formation. So comparing a rap-
idly proliferating cancer cell to a normal 
quiescent cell may yield differences in 
ROS attributable to differences in their 
metabolic rates rather than to the onco-
genic transformation. Addressing this 
problem requires a genetically compa-rable control cell line, preferably one 
that replicates some but not all of the 
genetic defects in the tumor cell line. 
This was precisely the approach used 
by Trachootham et al. in a report in this 
issue of Cancer Cell (Trachootham et al., 
2006). Using an immortalized epithelial 
cell line (T72 cells) that was incapable 
of forming tumors as controls, they then 
introduced an oncogenic version of RAS 
by transfecting them with H-RASV12, 
which conferred an ability to form tumors 
in a mouse xenograft model. In parallel 
experiments they overexpressed BCR-
ABL as a means of inducing oncogenic 
transformation, using a tet-inducible 
system. This permitted a comparison of 
multiple cell lines differing with respect 
to these oncogenes (Figure 1). Their 
data reveal that both of the transformed 
cell lines exhibited significantly greater 
levels of intracellular oxidative stress, Figure 1. Oncogenic transformation, oxidant stress, and cell survival in response to chemotherapeutic 
agents that augment rOs production175
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sitive probes. These results support the 
hypothesis that neoplastic transforma-
tion is associated with an increase in the 
basal level of oxidant stress.
In normal cells, proliferation resulting 
from growth factor stimulation requires 
ROS signaling. This is consistent with 
the idea that constitutive activation of 
this pathway in cancer cells is associ-
ated with a basal increase in oxidant sig-
naling. Of course, cancer can result from 
the activation, mutation, or suppression 
of a large number of genes, so these 
studies are not sufficient to conclude 
that all forms of cancer are necessar-
ily associated with an increase in ROS 
signaling.
Thioredoxin reductase is overex-
pressed in malignant cells
The degree of oxidant stress in 
a cell reflects a balance between the 
rate of ROS production and the activ-
ity of scavenging systems that detoxify 
them. Thioredoxin reductase-1 (TR1) 
is a selenoprotein that functions in the 
thioredoxin antioxidant system. A criti-
cal function of that system involves its 
translocation to the nucleus in response 
to oxidative stress, where it acts to main-
tain a reducing environment required for 
effective DNA binding of transcription 
factors and subsequent gene expression 
(Hirota et al., 1999). Paradoxically, TR1 is 
overexpressed in a variety of malignant 
tumors, and a loss of TR1 is associated 
with a reversal of tumor phenotype and 
a decrease in tumorigenicity (Yoo et al., 
2006). This increase in thioredoxin activ-
ity, in cells with exaggerated oxidant 
stress, may relate to its essential role 
in facilitating transcription in an environ-
ment where increased cytosolic oxidant 
stress signaling is required for stimulat-
ing cell proliferation.
Diverse chemotherapeutic agents 
can kill tumor cells by amplifying 
oxidant stress
Recent studies implicate increased 
oxidative stress in the cell death induced 
by diverse chemotherapeutic agents. 
Histone deacetylase inhibitors (Adachi 176 et al., 2004), proteasome inhibitors 
(Perez-Galan et al., 2006), and redox 
cycling agents (Lecane et al., 2005) 
all appear to increase oxidant stress in 
cells, although the mechanism responsi-
ble for the increase has not been estab-
lished. This common effect suggests that 
neoplastic cells may be more vulnerable 
to oxidant stress because they function 
with a heightened basal level of ROS-
mediated signaling, which is required 
for the increased rate of growth. If this 
idea is correct, then addition of an agent 
that increases ROS generation, or that 
decreases ROS scavenging capacity, 
may push a tumor cell beyond the break-
ing point in terms of lipid peroxidation, 
DNA damage, and protein oxidation. The 
study of Trachootham et al. supports this 
idea by showing that β-phenylethyl iso-
thiocyanate (PEITC) increases oxidant 
stress in transformed cells, possibly by 
generating ROS, but also by undermin-
ing the ability of the cells to detoxify 
oxidants. PEITC does this by depleting 
cellular levels of reduced glutathione 
(GSH), and by inhibiting the activity of 
glutathione peroxidase, a key cellular 
enzyme involved in the degradation of 
hydrogen peroxide. These effects were 
manifested by an increase in oxidation 
of cardiolipin, a lipid component of the 
mitochondrial inner membrane, and by 
a decrease in mitochondrial potential. 
It also inhibited H-RAS activity, without 
affecting H-RAS protein levels. By con-
trast, control cells exhibited a smaller 
increase in oxidant stress because their 
baseline levels of oxidant signaling were 
smaller, so the depletion of GSH pre-
sumably had less severe consequences 
for the cellular redox environment.
To the extent that ROS toxicity 
induced by certain chemotherapeutic 
agents can be an effective means of 
selectively eradicating malignant cells, 
it is useful to consider the most effective 
way to exploit this strategy. Trachootham 
and colleagues find that PEITC aug-
ments oxidant stress by decreasing oxi-
dant scavenging, whereas other agents 
appear to increase ROS generation. Conceivably, combinations of agents 
with complementary mechanisms of 
action could prove to be more effective 
than single agents. Moreover, to the 
extent that different agents may induce 
ROS production or alter redox conditions 
in specific subcellular compartments 
such as the mitochondria, it is pos-
sible that significant synergy could be 
achieved by combining complementary 
agents, while still minimizing the effects 
on normal cells. Future studies that 
identify the specific subcellular compart-
ments affected by novel oxidant stress-
mediated chemotherapeutic agents are 
needed to address this possibility.
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